These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2420446)

  • 21. Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group Study.
    Von Hoff DD; Green S; Alberts DS; Stock-Novack DL; Surwit EA; Miller TP; Stephens RL
    Am J Clin Oncol; 1991 Jun; 14(3):193-4. PubMed ID: 1709556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine therapy in chronic lymphocytic leukemia (CLL).
    Keating MJ; Kantarjian H; Talpaz M; Redman J; McCredie KB
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):461-6. PubMed ID: 2464794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary toxicity associated with fludarabine monophosphate.
    Hurst PG; Habib MP; Garewal H; Bluestein M; Paquin M; Greenberg BR
    Invest New Drugs; 1987; 5(2):207-10. PubMed ID: 2443463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fludarabine therapy in macroglobulinemic lymphoma.
    Kantarjian HM; Alexanian R; Koller CA; Kurzrock R; Keating MJ
    Blood; 1990 May; 75(10):1928-31. PubMed ID: 1692487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
    Arima N; Mizoguchi H; Shirakawa S; Tomonaga M; Takatsuki K; Ohno R
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):619-29. PubMed ID: 10234292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study.
    Kish JA; Kopecky K; Samson MK; Von Hoff DD; Fletcher WS; Kempf RA; Muggia FM
    Invest New Drugs; 1991 Feb; 9(1):105-8. PubMed ID: 1709151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
    Keating MJ; Kantarjian H; Talpaz M; Redman J; Koller C; Barlogie B; Velasquez W; Plunkett W; Freireich EJ; McCredie KB
    Blood; 1989 Jul; 74(1):19-25. PubMed ID: 2473795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. An Illinois Cancer Center study.
    Kilton LJ; Benson AB; Greenberg A; Johnson P; Shapiro C; Blough R; French S; Weidner L
    Invest New Drugs; 1992 Aug; 10(3):201-4. PubMed ID: 1385353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia.
    Schilling PJ; Vadhan-Raj S
    N Engl J Med; 1990 Sep; 323(12):833-4. PubMed ID: 1697401
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.
    Weiss GR; Crowley J; Von Hoff DD; Taylor SA; Belt RJ; Coltman CA; Hynes HE; Costanzi JJ
    Cancer Treat Rep; 1986 Sep; 70(9):1123-4. PubMed ID: 2427196
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase I clinical trials with fludarabine phosphate.
    Von Hoff DD
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):33-8. PubMed ID: 1699281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma.
    Grever MR; Benedetti J; Balcerzak SP; Taylor SA; Miller TP; Dakhil SR
    Invest New Drugs; 1994; 12(3):259-61. PubMed ID: 7534752
    [No Abstract]   [Full Text] [Related]  

  • 33. A comprehensive phase I and II clinical investigation of fludarabine phosphate.
    Grever M; Leiby J; Kraut E; Metz E; Neidhart J; Balcerzak S; Malspeis L
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):39-48. PubMed ID: 1699282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of fludarabine phosphate for gastric adenocarcinoma. An Illinois Cancer Center trial.
    Kilton LJ; Ashenhurst JB; Wade JL; Schilsky RL; Shiomoto G; Blough RR; French SL; Benson AB
    Invest New Drugs; 1994; 12(2):163-6. PubMed ID: 7532162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate.
    List AF; Kummet TD; Adams JD; Chun HG
    Am J Med; 1990 Sep; 89(3):388-90. PubMed ID: 1697447
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.
    Hiddemann W; Rottmann R; Wörmann B; Thiel A; Essink M; Ottensmeier C; Freund M; Büchner T; van de Loo J
    Ann Hematol; 1991 Jul; 63(1):1-4. PubMed ID: 1715191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor lysis syndrome induced by fludarabine monophosphate: a case report.
    Nakhoul F; Green J; Abassi ZA; Carter A
    Eur J Haematol; 1996 Apr; 56(4):254-5. PubMed ID: 8641396
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial.
    Taylor SA; Crowley J; Vogel FS; Townsend JJ; Eyre HJ; Jaeckle KA; Hynes HE; Guy JT
    Invest New Drugs; 1991 May; 9(2):195-7. PubMed ID: 1714887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fludarabine phosphate therapy of non-Hodgkin's lymphoma.
    Hochster H; Cassileth P
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):63-5. PubMed ID: 1699284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.
    Decaudin D; Bosq J; Tertian G; Nedellec G; Bennaceur A; Venuat AM; Bayle C; Carde P; Bendahmane B; Hayat M; Munck JN
    J Clin Oncol; 1998 Feb; 16(2):579-83. PubMed ID: 9469344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.